Deal Trends, Part I: No Bridge Over the Drug-Discovery Divide
Executive Summary
Platform technology deals were the hot item and the strategic basis for a raft of biotechs. But if their technologies opened some bottlenecks, they've failed to speed up the discovery process significantly. Big Pharma, meanwhile, has cut its technology spending--for a variety of reasons, including the necessity of learning to integrate what they've bought. As a result, platform companies are changing course. Some are becoming product-oriented players; others are repackaging their service offerings to help drug firms finance larger drug discovery programs.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.